Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Christopher D. Lao, Chris Miller et al.|BMC Cancer|2017Cited by 412
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediatesVida Chitsazzadeh, Kenneth Y. Tsai, Cristian Coarfa et al.|Nature Communications|2016Cited by 159
LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)Alexander Stratigos, M.G. Fury, Aleksandar Sekulić et al.|Annals of Oncology|2020Cited by 14